Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood–brain barrier

Minjee Kim, Daniel J. Ma, David Calligaris, Shuangling Zhang, Ryan W. Feathers, Rachael A. Vaubel, Isabelle Meaux, Ann C. Mladek, Karen E. Parrish, Fang Jin, Cedric Barriere, Laurent Debussche, James Watters, Shulan Tian, Paul A. Decker, Jeanette E Eckel-Passow, Gaspar J. Kitange, Aaron J. Johnson, Ian F Parney, Panagiotis Z AnastasiadisNathalie Y.R. Agar, William F. Elmquist, Jann N Sarkaria

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Controversy exists surrounding whether heterogeneous disruption of the blood–brain barrier (BBB), as seen in glioblastoma (GBM), leads to adequate drug delivery sufficient for efficacy in GBM. This question is especially important when using potent, targeted agents that have a poor penetration across an intact BBB. Efficacy of the murine double minute-2 (MDM2) inhibitor SAR405838 was tested in patient-derived xenograft (PDX) models of GBM. In vitro efficacy of SAR405838 was evaluated in PDX models with varying MDM2 expression and those with high (GBM108) and low (GBM102) expression were evaluated for flank and orthotopic efficacy. BBB permeability, evaluated using TexasRed-3 kDa dextran, was significantly increased in GBM108 through VEGFA overexpression. Drug delivery, MRI, and orthotopic survival were compared between BBB-intact (GBM108-vector) and BBB-disrupted (GBM108-VEGFA) models. MDM2-ampli-fied PDX lines with high MDM2 expression were sensitive to SAR405838 in comparison with MDM2 control lines in both in vitro and heterotopic models. In contrast with profound efficacy observed in flank xenografts, SAR405838 was ineffective in orthotopic tumors. Although both GBM108-vector and GBM108-VEGFA readily imaged on MRI following gadolinium contrast administration, GBM108-VEGFA tumors had a significantly enhanced drug and gadolinium accumulation, as determined by MALDI-MSI. Enhanced drug delivery in GBM108-VEGFA translated into a marked improvement in orthotopic efficacy. This study clearly shows that limited drug distribution across a partially intact BBB may limit the efficacy of targeted agents in GBM. Brain penetration of targeted agents is a critical consideration in any precision medicine strategy for GBM.

Original languageEnglish (US)
Pages (from-to)1893-1901
Number of pages9
JournalMolecular Cancer Therapeutics
Volume17
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Glioblastoma
Heterografts
Pharmaceutical Preparations
Gadolinium
Precision Medicine
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Dextrans
Permeability
Neoplasms
SAR405838
Survival
Brain
In Vitro Techniques

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood–brain barrier. / Kim, Minjee; Ma, Daniel J.; Calligaris, David; Zhang, Shuangling; Feathers, Ryan W.; Vaubel, Rachael A.; Meaux, Isabelle; Mladek, Ann C.; Parrish, Karen E.; Jin, Fang; Barriere, Cedric; Debussche, Laurent; Watters, James; Tian, Shulan; Decker, Paul A.; Eckel-Passow, Jeanette E; Kitange, Gaspar J.; Johnson, Aaron J.; Parney, Ian F; Anastasiadis, Panagiotis Z; Agar, Nathalie Y.R.; Elmquist, William F.; Sarkaria, Jann N.

In: Molecular Cancer Therapeutics, Vol. 17, No. 9, 01.09.2018, p. 1893-1901.

Research output: Contribution to journalArticle

Kim, M, Ma, DJ, Calligaris, D, Zhang, S, Feathers, RW, Vaubel, RA, Meaux, I, Mladek, AC, Parrish, KE, Jin, F, Barriere, C, Debussche, L, Watters, J, Tian, S, Decker, PA, Eckel-Passow, JE, Kitange, GJ, Johnson, AJ, Parney, IF, Anastasiadis, PZ, Agar, NYR, Elmquist, WF & Sarkaria, JN 2018, 'Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood–brain barrier', Molecular Cancer Therapeutics, vol. 17, no. 9, pp. 1893-1901. https://doi.org/10.1158/1535-7163.MCT-17-0600
Kim, Minjee ; Ma, Daniel J. ; Calligaris, David ; Zhang, Shuangling ; Feathers, Ryan W. ; Vaubel, Rachael A. ; Meaux, Isabelle ; Mladek, Ann C. ; Parrish, Karen E. ; Jin, Fang ; Barriere, Cedric ; Debussche, Laurent ; Watters, James ; Tian, Shulan ; Decker, Paul A. ; Eckel-Passow, Jeanette E ; Kitange, Gaspar J. ; Johnson, Aaron J. ; Parney, Ian F ; Anastasiadis, Panagiotis Z ; Agar, Nathalie Y.R. ; Elmquist, William F. ; Sarkaria, Jann N. / Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood–brain barrier. In: Molecular Cancer Therapeutics. 2018 ; Vol. 17, No. 9. pp. 1893-1901.
@article{b0d8c46de6b3473db2f5f4071a52b540,
title = "Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood–brain barrier",
abstract = "Controversy exists surrounding whether heterogeneous disruption of the blood–brain barrier (BBB), as seen in glioblastoma (GBM), leads to adequate drug delivery sufficient for efficacy in GBM. This question is especially important when using potent, targeted agents that have a poor penetration across an intact BBB. Efficacy of the murine double minute-2 (MDM2) inhibitor SAR405838 was tested in patient-derived xenograft (PDX) models of GBM. In vitro efficacy of SAR405838 was evaluated in PDX models with varying MDM2 expression and those with high (GBM108) and low (GBM102) expression were evaluated for flank and orthotopic efficacy. BBB permeability, evaluated using TexasRed-3 kDa dextran, was significantly increased in GBM108 through VEGFA overexpression. Drug delivery, MRI, and orthotopic survival were compared between BBB-intact (GBM108-vector) and BBB-disrupted (GBM108-VEGFA) models. MDM2-ampli-fied PDX lines with high MDM2 expression were sensitive to SAR405838 in comparison with MDM2 control lines in both in vitro and heterotopic models. In contrast with profound efficacy observed in flank xenografts, SAR405838 was ineffective in orthotopic tumors. Although both GBM108-vector and GBM108-VEGFA readily imaged on MRI following gadolinium contrast administration, GBM108-VEGFA tumors had a significantly enhanced drug and gadolinium accumulation, as determined by MALDI-MSI. Enhanced drug delivery in GBM108-VEGFA translated into a marked improvement in orthotopic efficacy. This study clearly shows that limited drug distribution across a partially intact BBB may limit the efficacy of targeted agents in GBM. Brain penetration of targeted agents is a critical consideration in any precision medicine strategy for GBM.",
author = "Minjee Kim and Ma, {Daniel J.} and David Calligaris and Shuangling Zhang and Feathers, {Ryan W.} and Vaubel, {Rachael A.} and Isabelle Meaux and Mladek, {Ann C.} and Parrish, {Karen E.} and Fang Jin and Cedric Barriere and Laurent Debussche and James Watters and Shulan Tian and Decker, {Paul A.} and Eckel-Passow, {Jeanette E} and Kitange, {Gaspar J.} and Johnson, {Aaron J.} and Parney, {Ian F} and Anastasiadis, {Panagiotis Z} and Agar, {Nathalie Y.R.} and Elmquist, {William F.} and Sarkaria, {Jann N}",
year = "2018",
month = "9",
day = "1",
doi = "10.1158/1535-7163.MCT-17-0600",
language = "English (US)",
volume = "17",
pages = "1893--1901",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood–brain barrier

AU - Kim, Minjee

AU - Ma, Daniel J.

AU - Calligaris, David

AU - Zhang, Shuangling

AU - Feathers, Ryan W.

AU - Vaubel, Rachael A.

AU - Meaux, Isabelle

AU - Mladek, Ann C.

AU - Parrish, Karen E.

AU - Jin, Fang

AU - Barriere, Cedric

AU - Debussche, Laurent

AU - Watters, James

AU - Tian, Shulan

AU - Decker, Paul A.

AU - Eckel-Passow, Jeanette E

AU - Kitange, Gaspar J.

AU - Johnson, Aaron J.

AU - Parney, Ian F

AU - Anastasiadis, Panagiotis Z

AU - Agar, Nathalie Y.R.

AU - Elmquist, William F.

AU - Sarkaria, Jann N

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Controversy exists surrounding whether heterogeneous disruption of the blood–brain barrier (BBB), as seen in glioblastoma (GBM), leads to adequate drug delivery sufficient for efficacy in GBM. This question is especially important when using potent, targeted agents that have a poor penetration across an intact BBB. Efficacy of the murine double minute-2 (MDM2) inhibitor SAR405838 was tested in patient-derived xenograft (PDX) models of GBM. In vitro efficacy of SAR405838 was evaluated in PDX models with varying MDM2 expression and those with high (GBM108) and low (GBM102) expression were evaluated for flank and orthotopic efficacy. BBB permeability, evaluated using TexasRed-3 kDa dextran, was significantly increased in GBM108 through VEGFA overexpression. Drug delivery, MRI, and orthotopic survival were compared between BBB-intact (GBM108-vector) and BBB-disrupted (GBM108-VEGFA) models. MDM2-ampli-fied PDX lines with high MDM2 expression were sensitive to SAR405838 in comparison with MDM2 control lines in both in vitro and heterotopic models. In contrast with profound efficacy observed in flank xenografts, SAR405838 was ineffective in orthotopic tumors. Although both GBM108-vector and GBM108-VEGFA readily imaged on MRI following gadolinium contrast administration, GBM108-VEGFA tumors had a significantly enhanced drug and gadolinium accumulation, as determined by MALDI-MSI. Enhanced drug delivery in GBM108-VEGFA translated into a marked improvement in orthotopic efficacy. This study clearly shows that limited drug distribution across a partially intact BBB may limit the efficacy of targeted agents in GBM. Brain penetration of targeted agents is a critical consideration in any precision medicine strategy for GBM.

AB - Controversy exists surrounding whether heterogeneous disruption of the blood–brain barrier (BBB), as seen in glioblastoma (GBM), leads to adequate drug delivery sufficient for efficacy in GBM. This question is especially important when using potent, targeted agents that have a poor penetration across an intact BBB. Efficacy of the murine double minute-2 (MDM2) inhibitor SAR405838 was tested in patient-derived xenograft (PDX) models of GBM. In vitro efficacy of SAR405838 was evaluated in PDX models with varying MDM2 expression and those with high (GBM108) and low (GBM102) expression were evaluated for flank and orthotopic efficacy. BBB permeability, evaluated using TexasRed-3 kDa dextran, was significantly increased in GBM108 through VEGFA overexpression. Drug delivery, MRI, and orthotopic survival were compared between BBB-intact (GBM108-vector) and BBB-disrupted (GBM108-VEGFA) models. MDM2-ampli-fied PDX lines with high MDM2 expression were sensitive to SAR405838 in comparison with MDM2 control lines in both in vitro and heterotopic models. In contrast with profound efficacy observed in flank xenografts, SAR405838 was ineffective in orthotopic tumors. Although both GBM108-vector and GBM108-VEGFA readily imaged on MRI following gadolinium contrast administration, GBM108-VEGFA tumors had a significantly enhanced drug and gadolinium accumulation, as determined by MALDI-MSI. Enhanced drug delivery in GBM108-VEGFA translated into a marked improvement in orthotopic efficacy. This study clearly shows that limited drug distribution across a partially intact BBB may limit the efficacy of targeted agents in GBM. Brain penetration of targeted agents is a critical consideration in any precision medicine strategy for GBM.

UR - http://www.scopus.com/inward/record.url?scp=85053007285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053007285&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-0600

DO - 10.1158/1535-7163.MCT-17-0600

M3 - Article

C2 - 29970480

AN - SCOPUS:85053007285

VL - 17

SP - 1893

EP - 1901

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 9

ER -